Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a "Buy" rating on Coya Therapeutics with an $18.00 price target, implying roughly a 327.6% upside from the current stock price.
• Analyst consensus remains a "Moderate Buy" (five Buys, one Sell) with a $16.00 consensus target, while the stock trades around $4.21 with a market cap of about $98.8 million and a 12‑month range of $3.94–$7.75.
• Coya reported Q results showing an EPS miss (‑$0.34 vs. ‑$0.08 expected) and negative profitability metrics, though revenue of $3.96M beat estimates; the company is a clinical‑stage biotech advancing UNC‑45A‑targeting programs COY‑001 and COY‑002.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $18.00 target price on the stock. HC Wainwright's target price suggests a potential upside of 327.55% from the company's current price.

Several other brokerages also recently commented on COYA. Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. D. Boral Capital reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Finally, Wall Street Zen downgraded Coya Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $16.00.

Coya Therapeutics Stock Down 1.4%

COYA stock opened at $4.21 on Monday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $7.75. The stock has a market cap of $98.75 million, a P/E ratio of -3.31 and a beta of 0.23. The business's 50-day moving average price is $4.69 and its 200-day moving average price is $5.51.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The firm had revenue of $3.96 million during the quarter, compared to analysts' expectations of $1.93 million. On average, equities research analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in COYA. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter worth about $196,000. XTX Topco Ltd bought a new stake in Coya Therapeutics in the 4th quarter worth approximately $192,000. Dimensional Fund Advisors LP increased its stake in Coya Therapeutics by 58.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 31,429 shares of the company's stock worth $182,000 after acquiring an additional 11,648 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Coya Therapeutics during the 4th quarter worth approximately $145,000. Finally, Northwestern Mutual Wealth Management Co. bought a new position in shares of Coya Therapeutics during the 2nd quarter valued at approximately $119,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.